The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

By the age of 35, fertility rates drop significantly, with only about 66% of women able to conceive. As women approach ...

Yale researchers identified an underactive mTOR pathway as a cause of lissencephaly and reversed brain malformations in ...

Rapamycin is a kind of inhibitor that works in the way it inhibits the mTOR (mechanistic target of rapamycin) complex 1 that is involved in the regulation of cell growth and aging. Studies have ...

Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR ...

Researchers have identified a molecular mechanism driving the structural abnormalities leading to lissencephaly that have ...

tells India Today that Rapamycin, also known as sirolimus, was initially discovered by a bacterium on Easter Island (Rapa Nui ...

Some scientists say that rapamycin can reduce inflammation "by inhibiting a signaling pathway in the body called mTOR — which ...

Monepantel is under clinical development by Neurizon Therapeutics and currently in Phase II for Amyotrophic Lateral Sclerosis.